



30 June 2025

**Sunshine Lake Pharma Co., Ltd.**

HEC Scientific Park  
No. 368 Zhen'an Middle Road  
Chang'an Town, Dongguan City  
Guangdong Province  
the People's Republic of China  
Attn.: The Board of Directors

**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**

No. 38 Binjiang Road  
Yidu, Yichang  
Hubei Province  
People's Republic of China  
Attn.: The Board of Directors

Dear Sirs,

**PROPOSED CONDITIONAL PRIVATISATION OF YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. BY SUNSHINE LAKE PHARMA CO., LTD. BY WAY OF MERGER BY ABSORPTION OF YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. AND PROPOSED WITHDRAWAL OF LISTING**

We refer to the composite document dated 30 June 2025 jointly issued by Sunshine Lake Pharma Co., Ltd. and YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "**Composite Document**") in connection with the captioned subject. Capitalised terms used herein shall have the same meanings as those in the Composite Document unless otherwise stated.

We hereby give and have not withdrawn our written consent to the issue of the Composite Document with the inclusion therein of our opinions and reports, and the references to our name, opinions and reports in the form and context in which they respectively appear in the Composite Document.

We further confirm that, as at the Latest Practicable Date, we:


- (a) did not have any shareholding in any member of the Offeror Group or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Offeror Group; and

- (b) did not have any direct or indirect interest in any assets which had been since 31 December 2024 (the date to which the latest financial report of the Offeror Group were made up), acquired or disposed of by or leased to any member of the Offeror Group, or were proposed to be acquired or disposed of by or leased to any member of the Offeror Group.

We hereby further consent to this letter, the Valuation Report as set out in “APPENDIX II – VALUATION REPORT AND REPORTS FROM CICC AND KPMG” of the Composite Document and the valuation report appended to the Announcement, being made available on display during the period and at the relevant websites as set out in the paragraph headed “16. DOCUMENTS ON DISPLAY” in Appendix IV to the Composite Document.

Yours faithfully,

For and on behalf of  
China Sunrise Capital Limited

A handwritten signature in black ink, appearing to read 'Anthony Fong', written over a horizontal line.

Name: Anthony Fong  
Title: Managing Director